1. Home
  2. ENTO vs ADD Comparison

ENTO vs ADD Comparison

Compare ENTO & ADD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • ADD
  • Stock Information
  • Founded
  • ENTO 2014
  • ADD 2002
  • Country
  • ENTO United States
  • ADD United States
  • Employees
  • ENTO N/A
  • ADD N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • ADD Engineering & Construction
  • Sector
  • ENTO Health Care
  • ADD Consumer Discretionary
  • Exchange
  • ENTO Nasdaq
  • ADD Nasdaq
  • Market Cap
  • ENTO 2.9M
  • ADD 2.4M
  • IPO Year
  • ENTO 2016
  • ADD N/A
  • Fundamental
  • Price
  • ENTO $0.54
  • ADD $1.66
  • Analyst Decision
  • ENTO
  • ADD
  • Analyst Count
  • ENTO 0
  • ADD 0
  • Target Price
  • ENTO N/A
  • ADD N/A
  • AVG Volume (30 Days)
  • ENTO 62.4K
  • ADD 4.2M
  • Earning Date
  • ENTO 11-13-2024
  • ADD 10-17-2024
  • Dividend Yield
  • ENTO N/A
  • ADD N/A
  • EPS Growth
  • ENTO N/A
  • ADD N/A
  • EPS
  • ENTO N/A
  • ADD N/A
  • Revenue
  • ENTO N/A
  • ADD $2,830,442.00
  • Revenue This Year
  • ENTO N/A
  • ADD N/A
  • Revenue Next Year
  • ENTO N/A
  • ADD N/A
  • P/E Ratio
  • ENTO N/A
  • ADD N/A
  • Revenue Growth
  • ENTO N/A
  • ADD N/A
  • 52 Week Low
  • ENTO $0.19
  • ADD $1.42
  • 52 Week High
  • ENTO $9.35
  • ADD $185.00
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 43.76
  • ADD 29.58
  • Support Level
  • ENTO $0.52
  • ADD $1.71
  • Resistance Level
  • ENTO $0.62
  • ADD $2.46
  • Average True Range (ATR)
  • ENTO 0.06
  • ADD 0.34
  • MACD
  • ENTO -0.01
  • ADD 0.37
  • Stochastic Oscillator
  • ENTO 11.11
  • ADD 16.67

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About ADD Color Star Technology Co. Ltd.

Color Star Technology Co Ltd is an entertainment technology company with a network that focuses on the application of technology and artificial intelligence in the entertainment industry. It provides online entertainment performances and online education through its wholly-owned subsidiaries Color Metaverse and CACM. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.

Share on Social Networks: